



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Stanton et al.
SERIAL NUMBER : 10/600,007 EXAMINER : Jon Benjamin Ashen
FILING DATE : June 18, 2003 ART UNIT : 1635
FOR : APTAMER-TOXIN MOLECULES AND METHODS FOR USING
SAME

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Transmitted herewith for filing in the above-referenced patent application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (5 pages), in duplicate;
3. Copies of cited references B17-B22 and C101-C172;
4. Check No. 22536 in the amount of \$180 to cover the requisite filing fee of an Information Disclosure as set forth in 37 C.F.R. §1.117(p); and
5. Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

If the enclosed check is insufficient, the Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 23239-531. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer Number 30623

Dated: May 23, 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Stanton et al.
SERIAL NUMBER : 10/600,007 EXAMINER : Jon Benjamin Ashen
FILING DATE : June 18, 2003 ART UNIT : 1635
FOR : APTAMER-TOXIN MOLECULES AND METHODS FOR USING
SAME

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311. The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed. By virtue of the waiver under 37 CFR 1.98(a)(2)(i), copies of the U.S. Patents and Published Applications A36-A80 have not been submitted herewith.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by


APPLICANTS: **Stanton et al.**
U.S.S.N.: **10/600,007**

35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 23239-531.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to


Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: May 23, 2006

TRA 2154823v.1



Please type a plus sign (+) in this box

+

Modified Form 1449/PTO		Application Number	10/600,007
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	June 18, 2003
		First Named Inventor	Stanton et al.
		Group Art Unit	1635
		Examiner Name	Ashen, Jon Benjamin
		Attorney Docket Number	23239-531

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A36	3,710,795	01/16/73	Higuchi et al.			
	*A37	4,137,230	01/30/79	Hashimoto et al.			
	*A38	4,360,462	11/23/82	Higashide et al.			
	*A39	4,861,587	08/29/89	Kida et al.			
	*A40	4,808,520	02/28/89	Dattagupta et al.			
	*A41	4,959,309	09/25/90	Dattagupta et al.			
	*A42	5,142,047	08/25/92	Summerton et al.			
	*A43	5,262,564	11/16/93	Kun et al.			
	*A44	5,279,833	01/18/94	Rose			
	*A45	5,338,671	08/16/94	Scalice et al.			
	*A46	5,475,096	12/12/95	Gold et al.			
	*A47	5,496,938	03/05/96	Gold et al.			
	*A48	5,503,978	04/12/96	Schneider et al.			
	*A49	5,563,255	10/08/96	Monia et al.			
	*A50	5,567,588	10/22/96	Gold et al.			
	*A51	5,580,737	12/03/96	Polisky et al.			
	*A52	5,614,503	03/25/97	Chaudhary et al.			
	*A53	5,631,237	05/20/97	Dzau et al.			
	*A54	5,631,359	05/20/97	Chowrira et al.			
	*A55	5,637,459	6/10/97	Burke et al.			
	*A56	5,648,214	07/15/97	Nieuwlandt et al.			
	*A57	5,660,985	08/26/97	Pieken et al.			
	*A58	5,668,264	09/16/97	Janjic et al.			
	*A59	5,674,685	10/07/97	Janjic et al.			
	*A60	5,674,980	10/07/97	Frankel et al.			
	*A61	5,700,923	12/23/97	Goodchild et al.			
	*A62	5,707,796	01/13/98	Gold et al.			
	*A63	5,741,679	04/21/98	George et al.			
	*A64	5,789,157	08/04/98	Jensen et al.			
	*A65	5,763,177	06/09/98	Gold et al.			
	*A66	5,767,263	6/16/98	Usman et al.			

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Office	Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B17	EP	0 553 838	Kabushiki Kaisha Toshiba	08/04/93	
	B18	EP	0592035	Scalice et al.	04/13/94	
	B19	PCT	WO90/10448	Genentech, Inc.	9/20/90	
	B20	PCT	WO94/08050	Nexagen, Inc.	04/14/94	
	B21	PCT	WO98/18480	Nexstar Pharmaceuticals, Inc.	05/07/98	
	B22	PCT	WO02/26867	The Regents of the University of California	04/04/02	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C101	Agrawal and Zhang (1997) Ciba Found. Symp 209:60-78
	C102	Akhtar and Agrawal (1997), Trends Pharmacol. Sci 18(1):12-18
	C103	Antopolsky, <i>et al.</i> (1999), Bioconjug. Chem. 10(4): 598-606
	C104	Astriab-Fisher, <i>et al.</i> (2000), Biochem. Pharmacol. 60(1): 83-90
	C105	Bell, <i>et al.</i> (1999), In Vitro Cell. Dev. Biol. Anim. 35(9): 533-42
	C106	Bock et al., (1992) Nature 355:564-566
	C107	Brady <i>et al.</i> (2002) J. Med. Chem., 45:4706-4715
	C108	Carrasquillo, <i>et al.</i> (2003), Invest. Ophthalmology Vis. Sci. 44(1): 290-9
	C109	Chen et al. (1994) Biochem. 33:8746-8756
	C110	Chen, <i>et al.</i> (2003), Proc. Natl. Acad. Sci. U.S.A. 100(16): 9226-31
	C111	Church et al. (1984) PNAS USA 81:1991-1995
	C112	Cotten, <i>et al.</i> , (1991) Nucl. Acid Res. 19:2629-2635
	C113	Crooke (1997), Adv. Pharmacol. 40: 1-49
	C114	Daniels, <i>et al.</i> (2002), Anal. Biochem. 305(2): 214-26
	C115	Dehouck et al., (1996) Biology and Physiology of the Blood Brain Barrier, Couraud and Scherman eds., Chapter 23, pp. 143-146
	C116	de Smidt, <i>et al.</i> (1991), Nucleic Acids Res. 19(17): 4695-4700
	C117	Eggen and Georg, (2002) Medicinal Research Reviews, 22(2):85-101
	C118	Fedor and Uhlenbeck, (1990) Proc. Natl. Acad. Sci. USA 87: 1668-1672
	C119	Froehler <i>et al.</i> , (1986) Nucl. Acid Res. 14:5399-5467
	C120	Froehler <i>et al.</i> , (1986) Tet. Lett. 27:5575-5578
	C121	Gath et al., (1996) Biology and Physiology of the Blood Brain Barrier, Couraud and Scherman eds., Chapter 25, pp. 153-158
	C122	Green, <i>et al.</i> (1995), Chem. Biol. 2: 683-95
	C123	Greenwald, <i>et al.</i> , (1995) J. Org. Chem., 60:331-336
	C124	Griffin, <i>et al.</i> (1993), Gene 137(1): 25-31
	C125	Grindel, <i>et al.</i> (1998), Antisense Nucleic Acid Drug Dev. 8(1): 43-52
	C126	Hamann <i>et al.</i> (2002) Bioconjugate Chem., 13: 47-58
	C127	Hampel and Tritz, (1989) Biochemistry 28: 4929-4933

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C128	Harris <i>et al.</i> , (2003) Nature 2: 214-221
	C129	Haseloff and Gerlach, (1988) Nature 334: 585-591
	C130	Hirose <i>et al.</i> , (1978) Tet. Lett., 28:2449-2452
	C131	Hobbs, <i>et al.</i> , (1973) Biochemistry 12:5138-5145
	C132	Jablonski <i>et al.</i> , (1986) Nuc Acids Res. 14(15):6115-6128
	C133	Jashcke <i>et al.</i> , (1994) Nuc. Acids Res. 22:4810-4817
	C134	Jellinek, <i>et al.</i> (1995) Biochemistry 34(36): 11363-11372
	C135	Jenison, <i>et al.</i> (1998), Antisense Nucleic Acid Drug Dev. 8(4): 265-79
	C136	Kellogg <i>et al.</i> , (1994) BioTechniques 16:1134-1137
	C137	Khati, <i>et al.</i> (2003), J. Virol. 77(23): 12692-8
	C138	Koizumi <i>et al.</i> , FEBS Lett. 239: 285-288 (1988)
	C139	Kraus, <i>et al.</i> , (1998) Journal of Immunology 160:5209-5212
	C140	Lebedeva, <i>et al.</i> (2000), Eur. J. Pharm. Biopharm. 50(1): 101-119
	C141	Lewis, <i>et al.</i> , (2002) Bioconjugate Chemistry 13(6):1176-1180
	C142	Lin, <i>et al.</i> , (1994) Nucl. Acids Res. 22:5229-5234
	C143	Manoharan (2002), Antisense Nucleic Acid Drug Dev. 12(2): 103-128
	C144	Monteith and Levin (1999), Toxicol. Pathol. 27(1): 8-13
	C145	Padilla <i>et al.</i> , (2002) Nucleic Acids Research, 30(24):e138, pp. 1-4
	C146	Pagratris, <i>et al.</i> , (1997) Nat. Biotechnol 15:68-73
	C147	Peng, <i>et al.</i> (2001) Antisense Nucleic Acid Drug Dev. 11(1): 15-27
	C148	Pieken, <i>et al.</i> , (1991) Science 253:314-317
	C149	Pietersz, <i>et al.</i> (2001) Vaccine 19: 1397-1405
	C150	Reyderman and Stavchansky (1998) Pharmaceutical Research 15(6): 904-910
	C151	Richardson, <i>et al.</i> (2000), Biochem. Pharmacol. 59(9): 1045-1052
	C152	Richardson, <i>et al.</i> (2002), Chem. Res. Toxicol. 15(7): 922-926
	C153	Rothbard, <i>et al.</i> (2000), Nat. Med. 6(11): 1253-1257
	C154	Rothbard, J <i>et al.</i> (2002), J. Med. Chem. 45(17): 3612-3618
	C155	Ruckman, <i>et al.</i> (1998), J. Biol. Chem. 273(32): 20556-20567
	C156	Smith and Steitz (1997), Cell 89(5): 669-672
	C157	Smith <i>et al.</i> (1985) Nuc Acids Res. 13(7):2399-2412
	C158	Sood <i>et al.</i> , (1977) Nucl. Acid Res. 4:2757-2765
	C159	Sproat, <i>et al.</i> , Nucl. Acid Res. 19:733-738 (1991)
	C160	Srinivasan and Iversen (1995), J. Clin. Lab. Anal. 9(2): 129-137
	C161	Tavitian, <i>et al.</i> (1998), Nat. Med. 4(4): 467-471
	C162	Tanchou <i>et al.</i> (1994) Aids Research and Human Retroviruses 10:983-993
	C163	Tucker <i>et al.</i> , (1999), J. Chromatography B. 732: 203-212
	C164	Tuerk <i>et al.</i> , (1992) Proc. Natl. Acad. Sciences 89(15):6988-6992
	C165	Uhlenbeck, (1987) Nature 328: 596-600
	C166	Uhlmann, <i>et al.</i> (2000), Methods Enzymol. 313: 268-284

Express Mail No.:
Date of Deposit:

Page 5 of 5

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C167	Usman <i>et al.</i> (2000) Clin. Invest. 106:1197-1202
	C168	Vaish, <i>et al.</i> (2003), Biochemistry 42(29): 8842-8851
	C169	Vives, <i>et al.</i> (1997), J. Biol. Chem. 272(25): 16010-16017
	C170	Watson, <i>et al.</i> (2000), Antisense Nucleic Acid Drug Dev. 10(2): 63-75
	C171	Wlotzka, <i>et al.</i> (2002), Proc. Natl. Acad. Sci. U.S.A. 99(13): 8898-8902
	C172	Zubin, <i>et al.</i> (1999), FEBS Lett. 456(1): 59-62

*** By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents and Published Applications A36-A80 are not submitted.**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 2154717v.1